权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Circulating lipid and miRNA markers for early detection of breast cancer among women with abnormal mammograms

循环脂质和 miRNA 标记物用于乳房 X 光检查异常女性乳腺癌的早期检测

基本信息

批准号：
10218097
负责人：
Youping Deng
金额：
$ 56.93万
依托单位：
UNIVERSITY OF HAWAII AT MANOA
依托单位国家：
美国
项目类别：
财政年份：
2019
资助国家：
美国
起止时间：
2019-08-01 至 2024-07-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10218097
关键词：
American Cancer Society Anxiety Back Base Ratios Benign Biological Markers Biological Process Biopsy Blood Breast Breast Cancer Detection Breast Cancer Early Detection Breast Cancer Patient Breast biopsy Clinical Clinical Trials Cooperative Human Tissue Network Country Data Diagnosis Diagnostic tests Disease Early Diagnosis Gold Hawaii Human Individual Investigation Lesion Lipids Malignant Neoplasms Mammographic screening Mammography Membrane Methods MicroRNAs Monitor Pathologic Patients Phenotype Physiological Plasma Predictive Value of Tests Public Health Publishing Reverse Transcription Sampling Series Signal Transduction Technology Testing Time Training Validation Woman Work base breast cancer diagnosis breast imaging cancer biomarkers circulating microRNA classification algorithm cohort companion diagnostics cost cost effective diagnostic biomarker disease diagnosis early detection biomarkers follow-up lipidomics malignant breast neoplasm miRNA expression profiling microRNA biomarkers mortality novel novel marker patient response potential biomarker psychological distress tool

项目摘要

PROJECT SUMMARY Breast cancer is the most common cancer among women in the world. When breast cancer is found in early stages, it can be effectively treated or even cured, but treating a patient in later stages is very difficult. Thus, early detection of breast cancer is critical. Mammography is the current gold standard for breast cancer screening; however, most women with abnormal mammograms are eventually found not to have breast cancer. Fewer than 5 per 1,000 women actually have the disease when they are screened. Therefore, most abnormal mammograms are false positives that require further investigations including expensive breast imaging and biopsies, which can cause psychological distress. According to the American Cancer Society (ACS), about 10% of women who have a mammogram will be called back for more tests, but only 8% to 10% of those women will need a biopsy and 80% of those biopsies turn out to be benign. Therefore, the vast majority of the women would have undergone unnecessary investigations. Our aim is to identify circulating lipid and miRNA signatures that can be used reliably as a companion diagnostic tool together with screening mammography to reduce the number of unnecessary follow-up investigations, especially invasive biopsy. In our preliminary studies, we have identified a panel of 15 plasma lipid species that were able to distinguish early stage of cancer from benign lesions with over 90% accuracy. Using a ratio based normalization method, we have also found 5 paired plasma miRNA ratios that differentiate breast cancer from benign samples with over 90% accuracy. In order to validate our existing markers and identify potential novel markers, as well as integrate lipid and miRNA markers to increase the accuracy for early detection of breast cancer, we propose the following aims: 1. Validate and test the predictive value of circulating lipid markers for early detection of breast cancer. 2. Establish circulating miRNA markers for early detection of breast cancer. 3. Integrate circulating lipid and miRNA markers for early detection of breast cancer.

项目总结乳腺癌是世界上女性最常见的癌症。乳腺癌在早期发现时在晚期，它可以被有效地治疗甚至治愈，但在后期治疗病人是非常困难的。因此，乳腺癌的早期发现至关重要。乳房X光检查是目前乳腺癌的黄金标准。筛查；然而，大多数乳房X光检查异常的女性最终被发现没有乳房癌症。在接受筛查时，每1000名妇女中只有不到5人实际患有这种疾病。因此，大多数异常乳房X光检查是假阳性，需要进一步检查，包括昂贵的乳房成像和活组织检查，这可能会导致心理痛苦。据美国癌症协会称 (美国癌症协会)，大约10%的做过乳房X光检查的女性会被召回进行更多的检查，但只有8%到10% 其中，女性需要做活组织检查，80%的活组织检查结果是良性的。因此，广大的大多数女性都会接受不必要的调查。我们的目标是识别循环中的脂质和miRNA签名，这些签名可以可靠地作为伴侣使用诊断工具与筛查乳房X光检查相结合，减少不必要的随访次数检查，尤其是侵入性活检。在我们的初步研究中，我们已经确定了一个由15个血浆组成的小组能够区分早期癌症和良性病变的脂质种类，准确率超过90%。使用基于比率的归一化方法，我们还发现了5对区分的血浆miRNA比率从良性样本中提取乳腺癌的准确率超过90%。为了验证我们现有的标记和识别潜在的新标记，以及整合脂质和miRNA标记，以提高对对于乳腺癌的早期发现，我们提出了以下目标：1.验证和检验乳腺癌的预测价值循环血脂标记物用于乳腺癌的早期检测。2.建立循环中的miRNA标记用于乳腺癌的早期检测。3.早期整合循环脂质和miRNA标志物乳腺癌的检测。